10-K/A: Allied Corp. Files Amended 10-K, Reports on Operations and Strategic Shifts

Allied Corp.'s amended 10-K filing details its focus on Colombian cannabis production, commercial expansion, and strategic shifts away from US operations and clinical trials.

Summary

• Allied Corp., an international cannabis company, has filed an amendment to its Form 10-K for the fiscal year ended August 31, 2024, solely to include XBRL content.
• The company's primary focus is now on large-scale cannabis production in Colombia, leveraging its low production costs estimated at $0.05 to $0.12 per gram.
• Allied has successfully exported cannabis flower from Colombia and is establishing partnerships for distribution in Europe, Australia, and Poland.
• The company has scaled down production to approximately 600-800 flowers per month due to reaching the end of its quota, but has since been granted an increase to 50,000 kgs of THC cannabis flower.
• Allied has secured a 5-year agreement to supply 1.05 tons of cannabis flower annually to Poland, and a 3-year agreement for the UK market with a minimum of 200kg per year.
• The company has temporarily paused clinical trials for ALID-11, 11 and Psilonex to focus on Colombian cannabis production.
• Allied reported a net loss of $3,976,184 for the fiscal year ended August 31, 2024, compared to a net loss of $10,675,671 in the previous year.
• The company's management has expressed concerns about its ability to continue as a going concern due to recurring losses and negative cash flows.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in terms of production, international sales, and strategic partnerships, the company's financial situation and going concern issues raise significant concerns. The strategic shift away from US operations and clinical trials also adds a layer of uncertainty.

Positives

• Allied has achieved low production costs for cannabis in Colombia, estimated at $0.05 to $0.12 per gram.
• The company has secured significant supply agreements in Poland and the UK, ensuring future revenue streams.
• Allied has successfully completed international shipments of medical cannabis, demonstrating its ability to navigate complex supply chains.
• The company has increased its THC cannabis flower quota, allowing for greater production capacity.
• Allied has a strong agricultural genetics team and pharmaceutical background, which provides a competitive advantage.
• The company has met or exceeded European Pharmacopeia Standards, ensuring high-quality products.

Negatives

• Allied has a history of operating losses and has an accumulated deficit of $49,409,330.
• The company's management has expressed concerns about its ability to continue as a going concern.
• Allied has temporarily paused clinical trials for ALID-11, 11 and Psilonex due to fiscal constraints.
• The company is dependent on a limited number of customers for the majority of its revenue.
• Allied is involved in ongoing litigation in Nevada related to a building on land which was leased from FIORE who became insolvent.
• The company has a working capital deficit of $8,834,739.

Risks

• The company's ability to continue as a going concern is dependent on generating sufficient cash flow and obtaining additional capital.
• Allied is subject to risks related to regulatory compliance in the cannabis industry in the United States, Canada and Colombia.
• The company faces competition from other cannabis producers and may experience downward pricing pressure.
• Allied is reliant on third-party transportation services and importation services, which could lead to logistical problems and delays.
• The company is subject to cyber-security and privacy risks that could disrupt operations and expose it to financial losses.
• Allied may incur significant costs to defend its intellectual property and other proprietary rights.
• The company's operations in Colombia are subject to economic, political, and tax conditions prevalent in that country.
• The company is subject to the inherent risks involved with product recalls.
• The company's products could have unknown side effects.
• The company may not be able to maintain effective quality control systems.

Future Outlook

Allied Corp. is focused on commercial expansion and distribution to become a global leader in the supply of wholesale cannabis, with a focus on closing long-term recurrent contracts with minimum yearly commitments to secure its cash flow. The company plans to resume its focus on natural health products and brands after achieving profitability from the sale of its Colombia-produced cannabis.

Management Comments

• Our mission is to be a consistent and reliable supplier of high-quality medical cannabis to pharmaceutical companies globally.
• We aim to make cannabis a primary source of medicine accessible to all and improve patient lives throughout the world.
• Our management team believes that having control over our supply chain should enable us to provide a consistent, rolling-harvest supply to the global cannabis community.
• We believe our low production costs provide us with a competitive advantage.
• Our commitment to building and maintaining strong relationships with its partners and customers around the world has been a driving force behind its recent successes.
• The Company is dedicated to meeting the evolving needs of patients and healthcare professionals with its high-quality medical cannabis products, underpinned by rigorous quality standards and ethical cultivation & processing practices.
• We intend for our clients to access superior cannabis-related products developed with a high level of quality control.
• We believe our Bucaramanga, Colombia development and cultivation facility gives us a significant competitive advantage in our production of cannabis.
• Allied has established a track-record of producing high-quality product with consistent supply year-round at scale, while meeting European quality assurance.
• Allied has demonstrated its ability to harvest up to 1000 kgs per month of high-quality cannabis flower.
• Allieds recent successes are underpinned by what we consider to be one of Colombias leading agricultural genetics teams for cannabis production, combined with a strong pharmaceutical background.
• The aim is to bring the hospital and pharma background to the standard operating procedures and quality assurance of its Colombian based production.
• Allied has now executed on Part 1 (site identification and setup) and Part 2 (cultivation and export) of its plan.
• With this strong foundation, it is now implementing Part 3 of its journey: while continuing to leverage its Colombian cost advantages, cultivation know-how and pharma expertise, Allied is now focusing on distribution and commercialization to become the most reliable global wholesale cannabis supplier.
• The Board of Directors has made a conscious decision to prioritize and direct all available resources toward the success of our Colombian production and operations, as well as commercialization of our high-quality Colombian cannabis.
• The successful passing of audits and the commencement of commercial shipments reflect Allied's commitment to excellence, compliance, and reliability in meeting the demands of its international clientele.
• Most importantly, the business is demonstrating that it can not only sign commercial agreements, but also execute on delivery and be a reliable partner to navigate the complex medical cannabis supply chain.
• Following the attainment of company profitability through the successful production and sales of Colombian-grown cannabis, Allied Corp is poised to strategically resume its focus on natural health products and brands.
• We believe that our deal-making capabilities and experience will allow us to successfully identify, consummate and integrate acquisitions.
• We are actively fostering a culture of continued agility and exploration since the ability to pivot depending on market dynamics will deliver competitive advantage.

Industry Context

This announcement reflects a broader trend in the cannabis industry where companies are focusing on low-cost production in regions like Colombia to supply international markets. The emphasis on EU-GMP certification and establishing distribution partnerships is also a common strategy for companies seeking to expand their reach in the global medical cannabis market. The shift away from US operations and clinical trials indicates a strategic prioritization of immediate revenue generation over long-term development projects.

Comparison to Industry Standards

• Allied's reported production costs of $0.05 to $0.12 per gram are significantly lower than the estimated North American production costs of $1.00 to $2.00 per gram, giving them a competitive advantage.
• The company's focus on EU-GMP certification aligns with industry standards for exporting medical cannabis to European markets, similar to companies like Aurora Cannabis and Tilray.
• Allied's strategy of securing long-term supply agreements with distributors in Poland and the UK is comparable to other cannabis companies seeking to establish stable revenue streams.
• The company's decision to pause clinical trials to focus on production is a deviation from companies like GW Pharmaceuticals that prioritize pharmaceutical development, but is a common strategy for companies with limited resources.
• Allied's ability to harvest up to 1000 kgs per month of high-quality cannabis flower is a significant achievement, comparable to other large-scale cannabis producers in Colombia.
• The company's focus on meeting European Pharmacopeia Standards is a key differentiator, similar to companies like Canopy Growth that prioritize quality and compliance.

Management Changes

Legal Proceedings

• The company is involved in litigation in Nevada related to a building on land which was leased from FIORE who became insolvent.
• The company filed to have the court determine that the building belongs to the Company and/or the business that funded the acquisition of the building.

Related Party Transactions

• The company has entered into consulting agreements with entities controlled by Calum Hughes (Director & CEO), Paul Bullock (Director & COO), Jim Smeeding (Director & VP Pharmaceutical), Michael Moses (Chief Business Development Officer) and Ryan Maarschalk (CFO).
• The company settled outstanding payables with related parties through the issuance of common shares.
• The company received short-term loans from its key management personnel.

Stakeholder Impact

• Shareholders face the risk of dilution from future share issuances and the potential loss of investment due to the company's financial instability.
• Employees may be affected by potential cost-saving measures, including personnel reductions.
• Customers may benefit from the company's focus on high-quality, low-cost cannabis products.
• Suppliers may benefit from the company's increased production and distribution activities.
• Creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company will continue to focus on commercial expansion and distribution to become a global leader in the supply of wholesale cannabis.
• Allied will continue to leverage its Colombian cost advantages, cultivation know-how and pharma expertise.
• The company will focus on closing long-term recurrent contracts with minimum yearly commitments to secure its cash flow.
• Allied plans to resume its focus on natural health products and brands after achieving profitability from the sale of its Colombia-produced cannabis.
• The company will continue to explore strategic partnerships and pursue accretive acquisitions to supplement its organic growth.

Key Dates

Keywords

cannabis, Colombia, medical cannabis, THC, CBD, export, production, EU-GMP, supply chain, distribution, pharmaceutical, cultivation